NZ747726A - Nicotine particles - Google Patents
Nicotine particlesInfo
- Publication number
- NZ747726A NZ747726A NZ747726A NZ74772617A NZ747726A NZ 747726 A NZ747726 A NZ 747726A NZ 747726 A NZ747726 A NZ 747726A NZ 74772617 A NZ74772617 A NZ 74772617A NZ 747726 A NZ747726 A NZ 747726A
- Authority
- NZ
- New Zealand
- Prior art keywords
- nicotine
- particles
- less
- micrometres
- particle size
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims abstract description 209
- SNICXCGAKADSCV-JTQLQIEISA-N Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title claims abstract description 124
- 229960002715 Nicotine Drugs 0.000 title claims abstract description 114
- 229930015196 nicotine Natural products 0.000 title claims abstract description 114
- 239000000203 mixture Substances 0.000 claims abstract description 63
- 239000007788 liquid Substances 0.000 claims abstract description 46
- 238000001694 spray drying Methods 0.000 claims abstract description 20
- 239000000969 carrier Substances 0.000 claims abstract description 12
- 239000012530 fluid Substances 0.000 claims description 55
- 239000000843 powder Substances 0.000 claims description 44
- 238000003801 milling Methods 0.000 claims description 43
- 150000001413 amino acids Chemical class 0.000 claims description 31
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 30
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 29
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 28
- 235000000346 sugar Nutrition 0.000 claims description 25
- MMOPGICOOYBFJU-UHFFFAOYSA-N 3-(1-methylpyrrolidin-2-yl)pyridine;2-oxopropanoic acid Chemical compound CC(=O)C(O)=O.CN1CCCC1C1=CC=CN=C1 MMOPGICOOYBFJU-UHFFFAOYSA-N 0.000 claims description 8
- VWTHFJXLFGINSW-UHFFFAOYSA-N 2-hydroxypropanoic acid;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound CC(O)C(O)=O.CN1CCCC1C1=CC=CN=C1 VWTHFJXLFGINSW-UHFFFAOYSA-N 0.000 claims description 6
- SDVKWBNZJFWIMO-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound CN1CCCC1C1=CC=CN=C1.OC(=O)CC(O)(C(O)=O)CC(O)=O SDVKWBNZJFWIMO-UHFFFAOYSA-N 0.000 claims description 5
- 229940009098 Aspartate Drugs 0.000 claims description 5
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 5
- 125000000647 trehalose group Chemical group 0.000 claims 1
- 229960003136 leucine Drugs 0.000 description 26
- 235000001014 amino acid Nutrition 0.000 description 25
- 238000009826 distribution Methods 0.000 description 25
- 239000007921 spray Substances 0.000 description 19
- 239000002253 acid Substances 0.000 description 15
- LCTONWCANYUPML-UHFFFAOYSA-N pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 12
- 210000004072 Lung Anatomy 0.000 description 8
- 239000012458 free base Substances 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 239000004310 lactic acid Substances 0.000 description 8
- 235000014655 lactic acid Nutrition 0.000 description 8
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 6
- 229960004873 LEVOMENTHOL Drugs 0.000 description 6
- 229940041616 Menthol Drugs 0.000 description 6
- 229940107700 Pyruvic Acid Drugs 0.000 description 6
- 239000003434 antitussive agent Substances 0.000 description 6
- 238000000889 atomisation Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000010902 jet-milling Methods 0.000 description 4
- 230000011514 reflex Effects 0.000 description 4
- 238000005549 size reduction Methods 0.000 description 4
- 238000010977 unit operation Methods 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000010951 particle size reduction Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000003068 static Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BLUGYPPOFIHFJS-UUFHNPECSA-N (2S)-N-[(2S)-1-[[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 2
- 235000019454 L-leucine Nutrition 0.000 description 2
- 239000004395 L-leucine Substances 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000001965 increased Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 125000002524 organometallic group Chemical group 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 230000000391 smoking Effects 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- DNDWZFHLZVYOGF-KKUMJFAQSA-N (2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O DNDWZFHLZVYOGF-KKUMJFAQSA-N 0.000 description 1
- SKZDZXPBBYUFBY-WLHGVMLRSA-N (E)-but-2-enedioic acid;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound OC(=O)\C=C\C(O)=O.CN1CCCC1C1=CC=CN=C1 SKZDZXPBBYUFBY-WLHGVMLRSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- QLDPCHZQQIASHX-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound OC(=O)C(O)C(O)C(O)=O.CN1CCCC1C1=CC=CN=C1 QLDPCHZQQIASHX-UHFFFAOYSA-N 0.000 description 1
- AIBWPBUAKCMKNS-PPHPATTJSA-N 2-hydroxybenzoic acid;3-[(2S)-1-methylpyrrolidin-2-yl]pyridine Chemical compound OC(=O)C1=CC=CC=C1O.CN1CCC[C@H]1C1=CC=CN=C1 AIBWPBUAKCMKNS-PPHPATTJSA-N 0.000 description 1
- HDJBTCAJIMNXEW-PPHPATTJSA-N 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine;hydrochloride Chemical compound Cl.CN1CCC[C@H]1C1=CC=CN=C1 HDJBTCAJIMNXEW-PPHPATTJSA-N 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- 229940112141 Dry Powder Inhaler Drugs 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 229960000310 ISOLEUCINE Drugs 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 229940069688 Nicotine Bitartrate Drugs 0.000 description 1
- 229960005190 Phenylalanine Drugs 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N Raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 206010038683 Respiratory disease Diseases 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 229940035295 Ting Drugs 0.000 description 1
- VNDYJBBGRKZCSX-UHFFFAOYSA-L Zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002614 leucines Chemical class 0.000 description 1
- 108010049589 leucyl-leucyl-leucine Proteins 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- -1 ose Chemical compound 0.000 description 1
- 235000012771 pancakes Nutrition 0.000 description 1
- 108010026901 peptide 106 Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 229940102001 zinc bromide Drugs 0.000 description 1
Abstract
method includes combining nicotine with a liquid carrier to form a liquid mixture and spray drying the liquid mixture to form a first plurality of particles. The first pluralities of particles are then milled to form a second plurality of particles.
Description
NICOTINE PARTICLES
This disclosure relates to nicotine particles that are suitable for inhalation. The nicotine
particles are formed by spray drying followed by milling.
Dry powder rs (DPI) are known and are used to treat respiratory diseases by
delivering a dry powder comprising a pharmaceutically active compound, in aerosol form
h inhalation to the ts’ airways. ln pharmaceutical dry powders, the active
pharmaceutical ingredient (API) is usually agglomerated on the surface of larger carrier
particles, such as lactose for example. DPl’s operate complex mechanisms to ensure such
agglomerates disperse, break up or disaggregate before the API is inhaled into the lungs.
It may be difficult to deliver nicotine particles to the lungs at inhalation at air flow rates
that are within conventional smoking regime tion or air flow rates. Nicotine particles may
have a tendency to agglomerate and stick to inhaler or processing surfaces, especially as a size
of the nicotine particle deceases. Nicotine particles with an MMAD of less than about 10
micrometres tend to be increasingly thermodynamically unstable due to a high surface area to
volume ratio, which provides an increasing e free energy with this decreasing le
size, and consequently ses the tendency of particles to agglomerate and the strength of
the agglomerate. Forming nicotine particles may be difficult and costly.
ne particles may be ting when inhaled and may induce a cough reflex. Cough
suppressants such as menthol have been added to nicotine particle compositions. These cough
suppressants may have a tendency to agglomerate the nicotine particles and cause stickiness
of the composition. This may lead to handling and storage concerns of the nicotine particle
compositions.
It would be desirable to provide nicotine particles that may reduce or mitigate a cough
reflex when inhaled and provide an enhanced tion experience. It would be desirable that
the nicotine particles be formed and processed easily and exhibit a stable particle size
distribution. It may be desirable that the ne particles be free of a cough ssant
Nicotine particles may be formed by spray drying a liquid mixture to form a first plurality
of particles. The liquid mixture ses nicotine. The liquid mixture may also comprise a
W0 2018l002779
sugar, or an amino acid, or both a sugar and amino acid. The liquid e may comprise a
short peptide comprising 2 or 3 amino acid. The first plurality of particles is then milled to form a
second plurality of particles.
The second plurality of nicotine particles may have a particle size distribution where
about 90% the plurality of particles have a le size of less than about 2.8 micrometres, and
about 50% of the plurality of particles have a particle size of less than about 1.35 micrometres,
and about 10% of the second plurality of particles having a particle size of less than about 0.65
micrometres.
Preferably the milling step is performed with a fluid energy mill. The fluid energy mill may
1O decrease an average particle size or mass median aerodynamic diameter of the ne
particles.
Advantageously, the method described herein utilizes a spray dryer to provide
nous nicotine particles that can be further reduced in size with a fluid energy mill to
achieve a specific and controlled le size distribution. This method advantageously
maximizes product yield in a cost effective manner. The final size distribution of the second
plurality of nicotine particles may be stable over time and form a le composition. The final
size distribution of the second plurality of nicotine particles is sufficient to deliver nicotine to the
lungs at inhalation or air flow rates that are within conventional smoking regime inhalation or air
flow rates, to provide an enhanced tion experience
The term “nicotine” refers to ne and nicotine tives in any form, including but
not d to, a free-base nicotine, nicotine salt, or in a matrix such as a sugar matrix or
organometallic complex.
The term “amino acid" refers to a single unmodified or modified amino acid moiety,
preferably unmodified.
The term “short peptide" refers to a peptide comprising two or three amino acids.
The phrase “fluid energy milling” refers to particle size reduction by colliding particle
streams. Fluid energy milling includes air jet milling or jet milling.
W0 02779
The phrase “plurality of particles” unless otherwise specified, means the first plurality of
particles, the second plurality of les, or both the first and the second plurality of particles.
The size of a particle, stated , preferably refers to the aerodynamic diameter of the
particle. The aerodynamic diameter of a powder system is ably measured with a cascade
impactor. The term “MMAD” refers to the mass median aerodynamic diameter.
This disclosure relates to nicotine particles that are suitable for inhalation and methods
for forming the same. These nicotine particles may provide for gentle or smooth inhalation
without inducing or minimizing a cough reflex. The nicotine particles may be formed by spray
drying a liquid mixture to form a first ity of particles. The liquid mixture comprises nicotine
The liquid mixture may also se a sugar, or an amino acid, or both a sugar and amino
acid. Spray drying the liquid mixture may form a homogenous first plurality of particles. The first
plurality of particles may then be milled (preferably with a fluid energy mill) to form a second
plurality of particles having a size distribution that is reduced as compared to the size
distribution of the first plurality of particles. The second ity of nicotine les may have a
particle size distribution where about 90% (by ) of the plurality of particles have a particle
size of less than about 2.8 micrometres, and about 50% of the plurality of les have a
particle size of less than about 1.35 micrometres, and about 10% of the second plurality of
particles having a particle size of less than about 065 micrometres. The percentages relating to
particle size distribution bed herein are based on particle volume (% by volume) A dry
powder composition may be formed form these nicotine particles. An inhalation delivery
consumable element may contain the nicotine particles or dry powder composition described
herein.
The combination of spray drying followed by milling (preferably fluid energy milling)
advantageously provides nicotine particles that may be flowable, have a specific, controlled and
stable particle size distribution and provide an enhanced inhalation experience, Spray drying
forms a first ity of particles having a first size distribution. Advantageously, milling or fluid
energy milling decreases an e particle size of the particles, Milling or fluid energy milling
utilizes the first ity of particles and forms a second plurality of particles having a second
size distribution, The second size distribution is preferably reduced as compared to the first size
distribution.
W0 02779
The nicotine may be ved in the liquid carrier to form the liquid mixture. Sugar may
be dissolved in the liquid carrier to form the liquid e. An amino acid may be dissolved in
the liquid carrier to form the liquid mixture. A short peptide may be ved in the liquid carrier
to form the liquid mixture.
Spray drying utilizes a spray or atomization nozzle to atomize a liquid mixture (under
pressure) and evaporate liquid carrier from the liquid mixture. The resulting dry les may be
id shaped within a designed particle size distribution.
Fluid energy milling is a size reduction unit operation that utilizes colliding fluid streams
(for example gas or compressed gas or air) carrying particles. The colliding fluid streams
provide particle to particle impact to facilitate size reduction. There are generally no moving
parts in a fluid energy mill and generally no mechanical forces act on the particles during size
reduction.
Fluid energy or jet mills are typically capable of reducing solids to particle sizes in the
low—micron to submicron range. The size reduction energy is typically created by gas streams
from horizontal grinding air nozzles. Typically, particles in the fluidized bed created by the gas
streams are accelerated towards the center of the mill, colliding with slower moving particles or
particles moving in a different direction. The gas streams and the particles carried in them
typically create a violent turbulence and as the particles e with one another they are
reduced in size.
The second plurality of particles may be formed by fluid energy milling or ing air
streams with entrained ne particles. Preferably, the particle compositions of colliding air
streams are substantially similar and homogenous. Fluid energy milling may increase the
amount of respirable nicotine particles (particles able to reach the lungs) as compared to spray
dried only nicotine particles. Fluid energy milling may increase this amount by at least about
10% or at least about 20% or at least 30%.
The fluid energy milling step may reduce the particle size or average le size or
particle size distribution by about 10% or greater, or about 20% or greater. Larger particles may
be d a greater amount than smaller les in the same size distribution. For example
the 90% size threshold may be reduced (from the first size distribution 90% threshold to the
W0 2018l002779 2017/053710
second size distribution 90% threshold) by about 10% or greater, or about 20% or greater, or
about 30% or greater, or in a range from about 10% to about 40%, or from about 20% to about
40%.
The fluid energy milling step may reduce the mass median aerodynamic diameter of the
first plurality of particles to a mass median aerodynamic diameter of the second plurality of
particles by a ratio of about 1.1:1 to about 10:1, or about 1.21 to about 5:1, or about 1.221 to
about 3.6:1, or about 151 to about 3:1, or about 3:1, or about 2:1.
Preferably, the ratio of the mass median aerodynamic diameter of the first ity of
particles to the mass median aerodynamic diameter of the second plurality of particles is
1O between about 1.1:1 to about 10:1, or about 1.221 to about 5:1, or about 1.221 to about 3.6:1, or
about 1.5:1 to about 3:1, or about 3:1, or about 2:1.
The first plurality of particles may comprise about 90%, or about 95%, or about 98% of
particles having an aerodynamic diameter of about 4.5 etres or less. The first plurality of
particles may comprise at least about 50% of particles having an aerodynamic diameter of
about 2.5 micrometres or less. The first plurality of les may comprise at least about 10% of
particles having an namic diameter of about 0.85 micrometres or less. The first plurality
of particles may have a mass median aerodynamic diameter in a range from about 1 to about 4
micrometres. Substantially all of the first plurality of particles may have an aerodynamic
diameter in a range from about 500 nanometers to about 5 micrometres.
Fluid energy milling reduces the size of the first plurality of particles to form a second
plurality of les. The second plurality of particles may comprise at least about 90%, or about
95%, or about 98% of particles having an aerodynamic diameter of about 3 micrometres or less,
or 2.8 etres or less. The second plurality of particles may comprise at least about 50% of
particles having an aerodynamic diameter of about 1.5 micrometres or less, or 1.35
micrometres or less. The second plurality of particles may comprise at least about 10% of
particles having an aerodynamic diameter of about 0.7 micrometres or less, or 0.65
micrometres or less. The second plurality of particles may have a mass median aerodynamic
diameter in a range from about 1 to about 2.5 micrometres. Substantially all of the second
plurality of particles may have an aerodynamic diameter in a range from about 500 ters
to about 3 micrometres.
W0 2018l002779
The nicotine component of the particle may be a free base nicotine, a ne salt, or a
combination thereof. The nicotine component may be a nicotine salt formed by combining
nicotine or nicotine free base with an acid. The acid may be a stoichiometric amount of acid to
the nicotine free base, or a stoichiometric excess of acid may be combined with the nicotine free
base, or a stoichiometric excess of nicotine free base may be combined with the acid. A free
base nicotine may be utilized without the addition of an acid.
The acid may be an organic acid, an inorganic acid, or a Lewis acid. miting
es of inorganic acids are hydrochloric, hydrobromic, odic, nitric, sulfuric,
phosphoric, acetic, hexafluorophosphoric, and the like. miting es of organic acids
are levulinic, citric, gluconic, benzoic, nic, butyric, alicylic, maleic, lauric, malic,
fumaric, succinic, tartaric, amsonic, pamoic, mesylic, aspartic, formic, acetic, propionic, succinic,
camphorsulfonic, fumaric, isethionic, , mucic, para-toluenesulfonic, glycolic, glucuronic,
maleic, furoic, glutamic, benzoic, anthranilic, salicylic, phenylacetic, pyruvic, mandelic, embonic
(pamoic), methanesulfonic, ethanesulfonic, pantothenic, esulfonic (besylate), stearic,
sulfanilic, alginic, uronic, and the like. Non-limiting examples of Lewis acids are zinc
de or zinc bromide (ZnCI: / ZnBrz). These can react with nicotine to form organometallic
complexes.
Useful nicotine salts include, but are not limited to, nicotine pyruvate, nicotine citrate,
nicotine aspartate, nicotine lactate, nicotine bitartrate, nicotine salicylate, nicotine fumarate,
nicotine mono-pyruvate, ne glutamate or nicotine hydrochloride, for example. Preferred
nicotine salts include, nicotine lactate, nicotine pyruvate, nicotine citrate, nicotine aspartate, or a
combination thereof.
The pH of the plurality of particles (dissolved in water) may be in a range from about 5 to
about 9. Preferably the pH is about 7.0 or higher or in a range from 7.0 to 9.0. A pH of 9 can be
reached for a particle without c acid, while a pH of 5.0 can be obtained with the use of a
strong acid or diacid when forming the nicotine salt.
The ity of particles may include an amino acid or peptide (preferably formed of
three or less amino acids). The amino acid or peptide may reduce adhesion forces of the
particles and mitigate or prevent agglomeration of the particles during formation or subsequent
handling, The particles may form be a free flowing material and may possess a stable relative
le size distribution during sing, transport and storage.
W0 2018l002779
Useful amino acids may include leucine, alanine, valine, isoleucine, methionine,
phenylalanine, tyrosine, tryptophan, or a combination thereof. One red amino acid is
leucine or a leucine isomer such as, L—leucine. A useful peptide includes trileucine, for e
The plurality of particles may e a sugar. Sugar refers to simple sugars,
monosaccharides, disaccharides, and ccharides. Without limitation, examples of suitable
sugars are lactose, sucrose, raffinose, ose, fructose, dextrose, glucose, maltose, mannitol,
or combinations thereof. Preferred sugars include trehalose or mannitol.
The plurality of particles may contain less than about 30 wt% nicotine. The plurality of
particles may contain about 25 wt% or less nicotine or from about 15 to about 25 wt% nicotine.
1O The plurality of particles may n from about 1 to about 20 wt% nicotine or from about 10 to
about 20 wt% nicotine, or from about 5 to 15 wt% nicotine. The plurality of les may contain
from about 1 to about 10 wt% nicotine or from about 5 to about 10 wt% nicotine.
The plurality of particles may contain about 1 to about 10 wt% amino acid. The plurality
of particles may contain about 3 to about 7 wt% amino acid. The plurality of particles may
contain from about 5 wt% amino acid. The addition of the amino acid, especially L—leucine for
example, to the particles may reduce agglomeration or adherence to processing es.
The plurality of particles may contain about 60 to about 95 wt% sugar. The plurality of
particles may contain about 70 to about 90 wt% sugar.
Useful ne particles include an amino acid being leucine, a sugar being trehalose,
and a nicotine salt being nicotine lactate. The nicotine content may be from about 5 to about 15
wt% or about 9.5 wt%. The leucine content may be from about 3 to about 7 wt% or about 5
wt%. The molar ratio of acid:nicotine may be about 1:1.
Useful nicotine particles include an amino acid being leucine, a sugar being trehalose,
and a nicotine salt being nicotine e. The ne content may be from about 5 to about 15
wt% or about 9.6 wt%. The e content may be from about 3 to about 7 wt% or about 5
wt%. The molar ratio of acid:nicotine may be about 0.25:1.
Useful nicotine particles include an amino acid being leucine, a sugar being trehalose,
and a nicotine salt being nicotine pyruvate. The nicotine content may be from about 5 to about
W0 2018l002779
wt% or about 9.8 wt%. The leucine content may be from about 3 to about 7 wt% or about 5
wt%. The molar ratio of acid:nicotine may be about 0.6:1.
Useful nicotine particles include an amino acid being leucine, a sugar being trehalose,
and a nicotine salt being nicotine ate. The nicotine content may be from about 5 to about
wt% or about 9.3 wt%. The leucine content may be from about 3 to about 7 wt% or about 5
wt%. The molar ratio of acidznicotine may be about 06:1.
The particles may be formed by: (1) combining a nicotine, and optionally a sugar and an
amino acid or peptide in a liquid r to form a liquid mixture; (2) spray drying the liquid
mixture to form a first plurality of particles having a size in a range from about 0.5 to about 10
1O micrometres or in a range from about 0.5 to about 5 micrometres; and (3) milling the first
plurality of particles to form a second plurality of particles, Preferably the milling unit operation is
a fluid energy milling unit operation that reduces the size of the particles.
it has been found that preparing particles comprising nicotine by spray drying and then
milling (especially fluid energy milling) could improve the inhalation experience or mitigate or
reduce perceived harshness or a cough reflex associated with inhaling spray dried nicotine
particles. The examples below illustrate that that the perceived feel during inhalation of the
spray dried and further milled nicotine particles (with no cough ssant such as l)
compares favourably to spray dried and unmilled nicotine particles with 5% l cough
suppressant.
The plurality of particles may be free of a cough suppressant material. The plurality of
nicotine particles may comprises less than 5%, or less than 1%, or less than 0.1% by weight of
cough suppressant (such as menthol), or be free of cough suppressant (such as menthol).
The liquid r may be water, for example. The liquid mixture is flowable. The liquid
mixture is configured to flow h an atomization or atomizer nozzle to form a first plurality of
particles Then the first plurality of particles is fluid energy milled to form the precise size
distribution of second plurality of particles, described .
The plurality of particles described herein may form a dry powder composition and be
packaged for consumption. The les described herein may form a dry powder composition
and be packaged in an inhalation ry consumable element or contained within an inhalation
delivery consumable element. An inhalation delivery consumable element may be a capsule, for
W0 2018l002779
example. The capsule may be by disposed in an inhalation device, such as a dry powder
inhaler. The inhalation device may pierce the capsule and the particles may be entrained in the
inhalation air for delivery to the lungs of a consumer.
The plurality of particles or dry powder composition described herein and the inhalation
ry consumable element may be free of, or substantially free of carrier particles. The
plurality of les described herein and the inhalation delivery consumable t may be
free of, or substantially free of particles that are greater than about 20 etres, or greater
than about 50 etres, or greater than about 100 micrometres.
The plurality of les described herein may be processed at a reduced (as compared
to conventional nicotine particles) temperature that may result in reduced product loss. The
spray drying inlet temperature and the outlet temperature may be d. The spray drying
atomization pressure may be in a range from about 3 to about 7 bar, or 4 to about 6 bar, or
about 5 bar.
The spray drying inlet temperature may be about 140 degrees Celsius or less, or about
135 degrees Celsius or less, or about 130 degrees Celsius or less, or in a range from about 100
to about 150 degrees Celsius, or in a range from about 110 to about 140 degrees Celsius, or in
a range from about 125 to about 135 degrees Celsius. The spray drying outlet temperature may
be about 100 degrees s or less, or about 95 degrees Celsius or less, or about 90 degrees
Celsius or less, about 85 degrees Celsius or less, or about 80 degrees Celsius or less, or in a
range from about 30 to about 90 degrees s, or in a range from about 40 to about 90
degrees s, or in a range from about 50 to about 85 degrees Celsius.
The second plurality of particles may be formed by fluid energy milling the first plurality
of particles formed by the spray drying unit operation. The first plurality of particles may be
processed with a fluid energy mill by colliding the first plurality of particles with each other to
form the second plurality of particles or particles.
The first plurality of les (formed by the spray drying process) may be fluid energy
milled at a temperature of about 50 degrees Celsius or less, or about 40 degrees Celsius or
less, or about 30 degrees Celsius or less, about 20 degrees Celsius or less, or about 10
degrees s or less, or in a range from about -20 to about 40 degrees Celsius, or in a range
W0 2018l002779
from about —10 to about 30 degrees Celsius, or in a range from about 0 to about 30 degrees
Celsius.
The reduction in particle size by fluid energy milling may be increased by fluid energy
g at lower temperatures. The particles may tend to be more brittle at lower atures,
and may therefore fracture more y so that the milled les tend to be smaller at lower
temperatures. The first plurality of particles (formed by the spray drying process) may be fluid
energy milled at a temperature below room temperature, ably at a ature below
about 20 degrees Celsius, or below about 10 degrees Celsius, or below about 0 degrees
Celsius.
1O Fluid energy milling may be carried out at milling or ng pressures between about
0.1 and about 12 bar. Varying the pressure allows control over the amount of particle size
reduction. The milling pressure may be in a range from about 1 to about 7 bar, or about 2 to
about 6 bar, or about 3 to about 5 bar, or about 4 bar. Particle feed pressure may be greater
than the milling pressure. Feed pressure may be in a range from about 5 to about 13 bar, or
about 5 to about 10 bar, or about 6 to about 8 bar, or about 7 bar.
Fluid energy milling may be carried out in two or more stages, to e the cial
effects of the milling at different pressures. The use of multiple steps may allow one to tailor the
properties of the fluid energy milled particles to suit a particular inhaler device or to target
particular parts of the lung.
An additive al can be combined with the first plurality of particles and processed in
the fluid energy mill. Combining an additive material with the first plurality of particles may be
termed “co-jet or co-fluid energy” milling. The additive may coat the particles, depending on the
milling pressure.
The fluid energy mill may be any useful type of fluid energy mill. Useful fluid energy mills
include, for example, an Atritor M3 Spiral jet mill. a A850 Spiral jet mill, a MC50 Hosakawa
Microniser, other spiral jet mills, pancake jet mills or opposed fluid bed jet mills. The feed rate
for the fluid energy mill will depend on the size of the mill. Small spiral jet mills may use a feed
rate of, for example, about 1 to about 4 g per minute, whilst industrial scale mills will have a feed
rate in the order of kilograms per hour. Examples below utilize the Atritor M3 Spiral jet mill. This
W0 2018;002779
fluid energy mill provided at r than about 90% product yield or less than about a 10%
product loss.
The properties of the fluid jet milled particles may, to an extent, be ed or adjusted
by making changes to the fluid jet milling unit ion. For example, the degree of particle size
reduction may be adjusted by changing the number ofjets which are used in the fluid jet mill, or
by adjusting their orientation, that is, the angles at which they are positioned.
All scientific and technical terms used herein have meanings commonly used in the art
unless otherwise specified. The definitions provided herein are to facilitate understanding of
certain terms used frequently herein.
As used herein, the singular forms it n it
, an”, and “the" encompass embodiments having
plural referents, unless the content clearly dictates ise
As used herein, “or" is generally employed in its sense including “and/or” unless the
content clearly es otherwise. The term “and/or” means one or all of the listed elements or a
combination of any two or more of the listed elements.
As used , “have”, “having n uincluden ll ing 7) ncomprisen it
, , , , comprising” or the
like are used in their open ended sense, and generally mean “including, but not limited to”. It
will be understood that “consisting essentially of”, “consisting of”, and the like are subsumed in
“comprising," and the like.
The words “preferred” and “preferably” refer to embodiments of the invention that may
afford certain benefits, under certain circumstances. However, other embodiments may also be
preferred, under the same or other circumstances Furthermore, the recitation of one or more
red embodiments does not imply that other embodiments are not useful, and is not
intended to exclude other embodiments from the scope of the disclosure, including the claims.
is a schematic flow diagram of an rative method 100 of g the particles
135. The method 100 includes combining nicotine 102, a sugar 104, and an amino acid or
peptide 106 in a liquid carrier to form a liquid e 115 at block 110. Then, at block 120, the
liquid mixture 115 is spray dried to form a first plurality of particles 125. Then the first plurality of
2017/053710
particles 125 is milled at block 130 (fluid energy milled, for example) to form a second ity
of particles 135.
Examples
All the examples t Table 3 examples) are formulated by combining nicotine base
and acid in water (at the specified ratio) to form a stable nicotine salt solution. Then the sugar
and amino acid (leucine) is combined with the nicotine salt solution to form a liquid mixture.
Then the liquid mixture is atomized and dried to form dry particles that are collected to from the
dry powder composition.
The Table 3 examples are formulated by ing a nicotine free base with sugar and
amino acid ne) to form a liquid mixture. Then the liquid e is atomized and dried to
form dry particles that are collected to from the dry powder composition.
The spray dryer was a Buchi B-290 spray dryer (available from Buchi Corp., DE, USA).
The liquid mixture was provided to the spray dryer at a flow rate of 2 ml/min at 5 bar atomization
pressure. The outlet temperature was about 80 degrees Celsius for examples utilizing
trehalose. Table 1 below describes lactic acid nicotine powder formulations. Table 2 below
describes pyruvic acid nicotine powder formulations. Table 3 below describes no acid nicotine
powder formulations. Table 4 reports the particle size distribution of various examples.
Table 1 - Lactic Acid Nicotine Powder Formulations
Example Formulation pH of Comments
powder
solution
L1 10% Nicotine, Lactic acid (1:1), 7.3 Small amount of powder adhering
85% ose to spray dryer surface
% Nicotine, Lactic acid (1 :1), Small amount of powder adhering
77% Trehalose to spray dryer surface
L3 10% Nicotine, Lactic acid (1 :1), 7.5 Free flowing powder — no
WO 20181002779
80% Trehalose, 5% Leucine ‘ nce
L4 15% Nicotine, Lactic acid (1 :1), 7.1 Free flowing powder —- no
72% Trehalose, 5% Leucine adherence
L5 20% Nicotine, Lactic acid (1:1), —— Free flowing powder — no
64% Trehalose, 5% Leucine adherence
Table 2 - Pyruvic Acid Nicotine Powder Formulations
e Formulation pH of Comments
powder
solution
P1 10% Nicotine, Pyruvic acid (06:1), 7.5 Powder adhering to spray dryer
87% Trehalose surface, cohesive powder
P2 15% Nicotine, Pyruvic acid (06:1), 7.8 Cohesive powder, some static
80% Trehalose charge
P3 10% ne, Pyruvic acid (06:1), 7.7 Free flowing powder — no
82% Trehalose, 5% Leucine adherence, some static charge
P4 15% Nicotine, Pyruvic acid (06:1), 7.8 Free flowing powder — no
75% Trehalose, 5% Leucine adherence
P5 20% ne, Pyruvic acid (0.621), 7.7 Free flowing powder — no
68% Trehalose, 5% Leucine adherence
WO 02779
Table 3 - No Acid Nicotine Powder Formulations
Example Formulation pH of Comments
powder
N1 10% Nicotine, 90% Trehalose 9.3 Some powder adhering to spray
dryer surface
N2 15% Nicotine, 85% Trehalose 9.5 Some powder adhering to spray
dryer surface
N3 10% Nicotine, 85% Trehalose, 5% 8.6 Free flowing powder — no
Leucine adherence, some static charge
N4 15% Nicotine, 80% Trehalose, 5% 8.7 Free flowing powder — no
Leucine nce
N5 20% Nicotine, 75% Trehalose, 5% Free flowing powder — no
Leucine adherence
Table 4 — Particle Size Distribution — reported in micrometres
Example X10 X50 X90 VMD
L1 0.65 1.43 3.54 1.81
L2 0.68 1.62 3.75 1.97
L3 0.76 1.89 3.86 2.14
L4 0.92 2.14 3.99 2.35
L5 0.78 1.95 3.90 2.19
P1 0.67 1.54 3.47 1.85
P2 0.67 1.53 3.54 1.86
P3 0.66 1.48 3.54 1.84
P4 0.72 1.78 3.79 2.06
P4 0.65 1.43 3.54 1.81
N1 0.68 1.62 3.75 1.97
N2 0.76 1.89 3.86 2.14
N3 092 2.14 3.99 2.35
N4 0.78 1.95 3.90 2.19
N5 067 1.54 3.47 1.85
X10 refers to size of particle where 10% of particles, by volume, are less than this size.
X50 refers to size of particle where 50% of particles, by volume, are less than this size.
X90 refers to size of particle where 90% of particles, by volume, are less than this size.
VMD refers to volume mean diameter.
le size distribution described herein was determined by Sympatec laser sizing, Andersen
Cascade lmpactation, and ng on microscopy.
Table 5 — Further Formulations
Example Formulation X10 X50 X90 VMD MMADJ
1 10% Nicotine, Lactic Acid (1:1), 092 2.17 4.15 2.4 3.8
80% Trehalose, 5% Leucine
2 10% Nicotine, Pyruvic Acid (1 :06), 1.04 2.56 5.08 2.9 4.0
82% Trehalose, 5% Leucine
3 10% Nicotine, Citric Acid 5), 0.81 2.34 5.48 2.8 3.5
82% Trehalose, 5% Leucine
4 10% Nicotine, Aspartic Acid (1:06), 0.82 2.24 4.96 2.6 4.2
80% Trehalose, 5% Leucine
Fluid Energy Milling Examples
The ing examples are formulated as bed above. Example 5 includes 5% wt
menthol that is dissolved in ethanol and added to the liquid mixture. Example 6 is free of
menthol.
The liquid mixture is atomized and dried with a spray dryer to form dry particles that are
then fluid energy milled to from the dry powder composition.
The spray dryer was a Buchi B—290 spray dryer (available from Buchi Corp, DE, USA).
The liquid mixture was provided to the spray dryer at a flow rate of 2 ml/mln at 5 bar atomization
pressure. The outlet temperature was about 80 degrees Celsius for examples ing
trehalose.
The fluid energy mill was an Atritor M3 Fluid Energy Mill (available from Atritor d,
England). The feed rate to the mill was about 3 grams per minute, using a compressed air
driven venture feed at a pressure of about 7 bar and a milling pressure of about 4 bar, at room
temperature. Example 5 was milled to create Example 5M and Example 6 was milled to create
Example 6M.
Table 6 - Nicotine Powder Formulations
Example Formulation pH of powder solution
5% Nicotine, Lactic Acid (1 :1), 7.3
82% Trehalose, 5% e, 5% Menthol
6 5% Nicotine, Lactic Acid (1 :1), 7-2
82% Trehalose, 5% Leucine
Example 5 and Example 6 are then fluid energy milled as bed above. Prior to fluid
energy milling Example 6 had a respirable particle fraction of 52% (able to reach the lungs
2017/053710
during inhalation). After fluid energy milling Example 6M had a respirable le fraction of
70% (able to reach the lungs during inhalation).
Table 7 ~ Particle Size Before and After Fluid Energy Milling
Table 8 reports particle size distribution immediately following (t=0) and 7 days (t=7)
following spray drying and fluid energy milling. Storage conditions were 40 degrees Celsius and
75% relative humidity (RH) for seven days.
Table 8
Example X10 X50 X90 VMD Moisture
Content
t=0 0.74 1.79 3.61 2.02 t 2.59
t=7 0.74 1.80 3.66 2.05 t 2.32
5M t=0 0.62 1.14 2.32 1.33 t 2.32
5M t=7 0.62 1.19 2.50 1.14 2.98
6 t=0 0.82 2.03 4.03 2.27 2.77
6 t=7 0.80 2.03 4.05 2.27 3.02
6M t=0 0.65 1.34 2.80 1.56 2.94
6M t=7 0.64 1.32 2.80 1.56 2.99
Expert panel tests were conducted on Example 5 and Example 6 and Example 6M.
Example 6M and Example 5 were deemed to be substantially equal in ved inhalation feel
as compared to Example 6.
W0 2018l002779
Claims (15)
1. A , comprising: combining nicotine with a liquid carrier to form a liquid e; and spray drying the liquid e to form a first plurality of particles; and milling the first plurality of nicotine particles to form a second plurality of particles.
2. The method according to claim 1, wherein the combining step further comprises combining a sugar and the nicotine with the liquid carrier to form the liquid mixture.
3. The method according to any one of the ing claims, wherein the combining step comprises combining an amino acid and the nicotine with the liquid carrier to form the liquid mixture. 15
4. The method according to any one of the preceding claims wherein the nicotine is a nicotine salt.
5. The method according to any one of the preceding claims, wherein the milling step ses fluid energy milling and the fluid energy milling decreases a mass median 20 aerodynamic diameter of the first plurality of particles to a mass median aerodynamic diameter of the second plurality of particles by a ratio of about 1.2:1 to about 5:1.
6. The method according to any one of the preceding claims, wherein the spray drying step forms a first plurality of nicotine particles sing about 90% by volume of the particles 25 having a particle size of about 4.5 micrometres or less, and about 50% by volume of the W0 2018l002779 particles having a particle size of less than about 2.5 etres and about 10% by volume of the particles having a particle size of less than about 0.85 micrometres.
7. The method according to any one of the preceding claims, wherein the milling step forms a second plurality of nicotine particles comprising about 90% by volume of the particles having a le size of less than about 3.0 micrometres, and about 50% by volume of the particles having a particle size of less than about 1.5 micrometres, and about 10% by volume of the particles having a particle size of less than about 0.7 micrometres. 10
8. The method according to claim 2, wherein the ne comprises nicotine e, nicotine pyruvate, nicotine citrate, or nicotine aspartate, and the sugar is trehalose.
9. The method according to claim 3, wherein the nicotine comprises nicotine lactate, nicotine pyruvate, nicotine citrate, nicotine aspartate, and the amino acid comprises leucine.
10. The method according to any one of the preceding claims further comprising ing the second plurality of particles in an inhalation delivery consumable t.
11. A dry powder composition, comprising: 20 a plurality of particles formed of ne, a sugar, and an amino acid, wherein about 90% by volume of the particles have a particle size of less than about 28 micrometres, and about 50% by volume of the particles have a particle size of less than about 1.35 micrometres. and about 10% by volume of the particles have a particle size of less than about 0465 micrometres.
12. The dry powder ition according to claim 11 n, the nicotine comprises nicotine lactate, nicotine pyruvate, nicotine citrate, nicotine aspartate, and the sugar comprises trehalose and the amino acid comprises leucine.
13. The dry powder ition according to claim 11 or 12, comprising about 5 to about 15 wt% nicotine.
14. The dry powder composition of any one of claims 11 to 13, comprising about 60 wt% to about 95 wt% sugar, and about 1 wt% to about 10 wt% amino acid.
15. An inhalation delivery consumable element containing the dry powder composition of any one of claims 11 to 14. WO 02779 ’/—— 100 104 102
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16177156.3 | 2016-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ747726A true NZ747726A (en) |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US12048762B2 (en) | Nicotine particles | |
US20210361567A1 (en) | Nicotine particles and compositions | |
JP6672258B2 (en) | Nicotine preparation and method for producing the same | |
RU2484823C2 (en) | Compositions for treating parkinson's disease | |
EP2398464B1 (en) | Pharmaceutical composition for inhalation | |
WO2003035051A2 (en) | The use of proton sequestering agents in drug formulations | |
AU2003273273B2 (en) | Trospium containing compositions | |
JP2023171770A (en) | Inhalable composition of clofazimine and methods of use thereof | |
EP2368548B1 (en) | Dry powder pharmaceutical composition for inhalation | |
NZ747726A (en) | Nicotine particles | |
AU2021332085B2 (en) | Glucosidase inhibitors for the treatment and prevention of pulmonary infections | |
NZ747471A (en) | Nicotine particles and compositions | |
US20240299379A1 (en) | Compositions of clofazimine and amikacin for pulmonary administration in the treatment of respiratory diseases | |
IL263540B2 (en) | Microparticles comprising a sulphur-containing compound | |
Ambrus et al. | Development of dry powder carrier systems for pulmonary application | |
CN118806738A (en) | Pharmaceutical preparation for inhalation and application thereof in medicine | |
Ambrus et al. | Aerodynamic and structural evaluation of microcomposites containing meloxicam potassium |